CytomX Therapeutics, Inc. (CTMX): restructuring charge — CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway

CytomX Therapeutics, Inc.

Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.
Estimated restructuring charges of $5M to $6M, mostly severance, recorded in Q1 2025.
Cash payments of ~$5M starting Q1 2025; cash runway extended into Q2 2026.
Company to prioritize CX-2051 (EpCAM PROBODY ADC) and support research collaborations.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

CytomX Therapeutics, Inc. announced a restructuring with charges of approximately $5 million to $6 million affecting general and administrative functions and staff supporting non-partnered internal research programs (approximately 40%).

Type: restructuring
Charge: approximately $5 million to $6 million
Affected area: general and administrative functions and staff supporting non-partnered internal research programs
Headcount: approximately 40%

Exact text from the filing

cash runway into the second quarter of 2026. In connection with the restructuring, the Company estimates that it will incur aggregate restructuring charges of approximately $5 million to $6 million, which the Company expects will be substantially recorded in the first quarter of 2025. The estimated restructuring charges are related primarily to one-time

View on SEC.gov

Browse all restructurings & charges →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-002165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.